论文部分内容阅读
目的比较羟考酮缓释片与华蟾素注射液对中重度癌痛的临床疗效。方法 288例中重度癌痛患者,随机分为羟考酮组和华蟾素组,每组144例。羟考酮组口服羟考酮缓释片,华蟾素组静脉滴注华蟾素注射液,观察比较两组患者的疼痛缓解情况、生活质量评分以及不良反应发生情况。结果羟考酮组的疼痛缓解率为82.64%,显著高于华蟾素组的66.67%(P<0.05);治疗后,两组患者疼痛情况控制良好,KPS评分显著高于治疗前(P<0.05);但两组治疗后KPS评分比较差异无统计学意义(P>0.05);治疗后,羟考酮组的不良反应发生率为51.39%,显著低于华蟾素组的68.75%(P<0.05)。结论羟考酮缓释片治疗中重度癌痛患者疗效显著,不良反应发生率低,可提高患者的生活质量,具有较大的临床应用价值。
Objective To compare the clinical effects of oxycodone sustained-release tablets and cinobufacini injection on patients with moderate-severe pain. Methods 288 patients with moderate to severe cancer pain were randomly divided into oxycodone group and cinobufotalin group, 144 cases in each group. Oxycodone oxycodone sustained-release tablets and cinobufacini group were injected intravenously with cinobufacini injection. The pain relief, quality of life score and incidence of adverse reactions in both groups were observed and compared. Results The pain relief rate was 82.64% in oxycodone group, which was significantly higher than that in cinobufacini group (66.67%, P <0.05). After treatment, pain in both groups was well controlled and KPS score was significantly higher than before treatment (P <0.05) (P <0.05). After treatment, the incidence of adverse reactions in oxycodone group was 51.39%, which was significantly lower than 68.75% in cinobufotalin group (P <0.05), but there was no significant difference between the two groups ). Conclusion Oxycodone sustained-release tablets for the treatment of patients with moderate-severe cancer have a significant effect, low incidence of adverse reactions, can improve the quality of life of patients with greater clinical value.